RE:RE:RE:Awareness They are increasingly making the case around Lipo as a co-indicator for many other issues around PLWH and have to think that may be a little bit of the extra around Egrifta sales, retention and how they came up with that new market size and market share objective they're shooting for with MSLs and all the "soft" educational pitches they now make. Every little small bit helps a lot given the margins on that product for THTX.
The only thing in their control to show the market it's cheap is to get the market to solidly believe they will show $90+mil in sales, drop expenses down to cashflow breakeve, and project $100mil and net profits for next year. That's pretty much the only thing at this point. Any pipeline progress woudl be great, but icing on top --just hit numbers and surprise above the low end. Restore a shred of confidence in the companies assets, which at this point, as you say, are way below fair value because of many reasons we all know. Start it tomorrow, that's all we can hope for.....oh, and a huge partnership on someothing!